1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsHarnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders SBIR/STTR is sponsored by National Institute on Drug Abuse (NIDA). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
The mHealthHub is a virtual forum where technologists, researchers and clinicians connect, learn, share, and innovate on mHealth tools to transform healthcare. 365 Innovation Drive, Suite 335, Memphis, TN 38152 Stay up-to-date on the latest mHealth news and training.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants Use Disorders (OUD/StUD) R41/42 STTR ( RFA-DA-24-038 ) R43/44 SBIR ( RFA-DA-23-021 ) Due dates: February 14, 2024; August 13, 2024; February 14, 2025 Award Budget: Total funding support may not exceed $400,000 for Phase I awards and $3,000,000 for Phase II awards.
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders R41/42 STTR ( RFA-DA-25-053 ) R43/44 SBIR ( RFA-DA-25-054 ) Award Budget: Total funding support may not exceed $400,000 for Phase I awards and $3,000,000 for Phase II awards. NIDA’s mission is to advance science on drug use and addiction and to apply that knowledge to improve individual and public health.
This involves: Strategically supporting and conducting basic and clinical research on drug use (including nicotine), its consequences, and the underlying neurobiological, behavioral, and social mechanisms involved.
Ensuring the effective translation, implementation, and dissemination of scientific research findings to improve the prevention and treatment of substance use disorders and enhance public awareness of addiction as a brain disorder. For more information about NIDA, visit their website . The Voice AI Summer School 2024 – Now Accepting Applications MOODS Stress & Stressor Tracking App Available for Research Studies
According to the current listing, eligibility includes: Small businesses. Confirm the full requirements in the official notice before applying.
The current listing shows up to $400,000 for Phase I; up to $3,000,000 for Phase II. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders SBIR/STTR is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article